CCDC201: A Promising Drug Target and Biomarker for Chronic Pain Management

Target Name: CCDC201

NCBI ID: G114515518

CCDC201

Other Name(s): Coiled-coil domain-containing protein 201 | Coiled-coil domain containing 201 | coiled-coil domain containing 201 | CC201_HUMAN

CCDC201: A Promising Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can have a significant impact on an individual's quality of life, including reduced productivity, increased stress, and loss of productivity. In addition, chronic pain can also have significant economic implications, with estimates suggesting that the costs of chronic pain conditions in the United States alone exceed $63 billion per year.

CDC201 is a protein that has been identified as a potential drug target and biomarker for the management of chronic pain. CCDC201 is a transmembrane protein that is expressed in various tissues, including the brain, spinal cord, and peripheral tissues. It is composed of a coiled-coil domain, which is responsible for its unique structure and function.

The CCDC201 Protein

The CCDC201 protein is a member of the subfamily of coiled-coil domain-containing proteins (CCDHs), which are a group of transmembrane proteins that are characterized by a coiled-coil domain. The CCDC201 protein is unique due to its specific structure, which is composed of a long alpha-helices that are coiled together to form a stable structure.

CDC201 is expressed in various tissues throughout the body, including the brain, spinal cord, and peripheral tissues. It is also known to be involved in several cellular processes, including cell signaling, neurotransmitter release, and pain perception.

CDC201 as a Potential Drug Target

The CCDC201 protein has been identified as a potential drug target for the management of chronic pain due to its involvement in pain perception and neurotransmission. Several studies have shown that changes in the expression of CCDC201 can contribute to the development and progression of chronic pain conditions.

One of the key features of CCDC201 is its ability to interact with various signaling pathways, including G-protein-coupled receptors (GPCRs) and neurotransmitter systems. GPCRs are a family of transmembrane proteins that are involved in cellular signaling, and they play a crucial role in mediating pain perception.

In addition to its interactions with GPCRs, CCDC201 has also been shown to interact with other signaling pathways, including the neurotransmitter system. The neurotransmitter system is a complex system that is involved in the transmission of chemical signals from the brain to other parts of the body, and it plays a crucial role in pain perception and management.

CDC201 as a Potential Biomarker

In addition to its potential as a drug target, CCDC201 has also been identified as a potential biomarker for the management of chronic pain. The ability of CCDC201 to interact with various signaling pathways makes it a potential indicator of pain sensitivity and the severity of pain.

CDC201 has been shown to play a role in the regulation of pain sensitivity and the perception of pain. Several studies have shown that changes in the expression of CCDC201 can contribute to increased pain sensitivity and the development of chronic pain conditions.

CDC201 has also been shown to be involved in the regulation of neurotransmitter systems, which are involved in the transmission of chemical signals from the brain to other parts of the body. changes in the expression of CCDC201 have been shown to affect neurotransmitter levels and contribute to the development of chronic pain conditions.

Conclusion

CDC201 is a protein that has been identified as a potential drug target and biomarker for the management of chronic

Protein Name: Coiled-coil Domain Containing 201

The "CCDC201 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC201 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets